Stone House Investment Management’s Indivior Pharmaceuticals INDV Stock Holding History

Stone House Investment Management’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$410	Buy	+10	New	+$363	﹤0.01%	1063

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Stone House Investment Management's INDV Position: Q2 2026 in Review

Stone House Investment Management opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 10 shares worth $410. The stake represents ﹤0.01% of the portfolio and ranks #1063 among its holdings.

336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

Stone House Investment Management held 10 shares of Indivior Pharmaceuticals worth $410 as of Q2 2026.
Indivior Pharmaceuticals was a new Stone House Investment Management position in Q2 2026.
Indivior Pharmaceuticals made up ﹤0.01% of Stone House Investment Management's portfolio in Q2 2026, its #1063 holding.
336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Stone House Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.